Arcturus’ unlocked nucleomonomer agents (UNAs) can improve the in vivo efficiency of small interfering RNA (siRNA)-mediated gene silencing and potentially improve the efficiency of messenger RNA (mRNA)-mediated protein replacement. UNAs are RNA analogues in which the C2′-C3′ bond of the ribose ring is absent (see figure below).
One or more UNAs can be positioned strategically along a nucleic acid strand to manipulate the chemical properties of the molecule. Addition of a single UNA in siRNA therapeutics can enable more efficient suppression of target protein production.
October 2, 2019
Arcturus Therapeutics to Present at Three Upcoming Investor Conferences
September 26, 2019
Arcturus Therapeutics Announces $9.8 Million Registered Direct Offering of Common Stock
September 23, 2019
Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. and Re-Appointment of Andy Sassine to the Board of Directors